References

Ahmed, RM, Devenney, EM, Irish, M, Ittner, A, Naismith, S, Ittner, LM, Rohrer, JD, Halliday, GM, Eisen, A, Hodges, JR & Kiernan, MC 2016, 'Neuronal network disintegration: common pathways linking neurodegenerative diseases', *Journal of Neurology, Neurosurgery & Psychiatry*, p. jnnp-2014-308350.

Allgrove, J, Clayden, GS, Grant, DB & Macaulay, JC 1978, 'Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production', *Lancet (London, England)*, vol. 1, no. 8077, pp. 1284–1286.

Arrasate, M & Finkbeiner, S 2012, 'Protein aggregates in Huntington's disease', *Experimental Neurology*, vol. 238, no. 1, pp. 1–11.

Barnham, KJ, Masters, CL & Bush, AI 2004, 'Neurodegenerative diseases and oxidative stress', *Nature Reviews Drug Discovery*, vol. 3, no. 3, pp. 205–214.

Barut, BA & Zon, LI 2000, 'Realizing the potential of zebrafish as a model for human disease', *Physiological Genomics*, vol. 2, no. 2, pp. 49–51.

Benavides, F & Guénet, JL 2001, '[Murine models for human diseases]', *Medicina*, vol. 61, no. 2, pp. 215–231.

Bence, NF, Sampat, RM & Kopito, RR 2001, 'Impairment of the ubiquitin-proteasome system by protein aggregation', *Science (New York, N.Y.)*, vol. 292, no. 5521, pp. 1552–1555.

Bertram, L & Tanzi, RE 2005, 'The genetic epidemiology of neurodegenerative disease', *Journal of Clinical Investigation*, vol. 115, no. 6, pp. 1449–1457.

Biglan, KM, Ross, CA, Langbehn, DR, Aylward, EH, Stout, JC, Queller, S, Carlozzi, NE, Duff, K, Beglinger, LJ & Paulsen, JS 2009, 'Motor Abnormalities in Premanifest Persons with Huntington's Disease: The PREDICT-HD Study', *Movement disorders : official journal of the Movement Disorder Society*, vol. 24, no. 12, pp. 1763–1772.

Bizzarri, C, Benevento, D, Terzi, C, Huebner, A & Cappa, M 2013, 'Triple A (Allgrove) syndrome: an unusual association with syringomyelia', *Italian Journal of Pediatrics*, vol. 39, p. 39.

Bourne, C, Clayton, C, Murch, A & Grant, J 2006, 'Cognitive impairment and behavioural difficulties in patients with Huntington's disease', *Nursing Standard (Royal College of Nursing (Great Britain): 1987)*, vol. 20, no. 35, pp. 41–44.

Brooks, BP, Kleta, R, Caruso, RC, Stuart, C, Ludlow, J & Stratakis, CA 2004, 'Triple-A syndrome with prominent ophthalmic features and a novel mutation in the *AAAS* gene: a case report', *BMC Ophthalmology*, vol. 4, p. 7.

Brown, RC, Lockwood, AH & Sonawane, BR 2005, 'Neurodegenerative Diseases: An Overview of Environmental Risk Factors', *Environmental Health Perspectives*, vol. 113, no. 9, pp. 1250–1256.

Butler, C & Zeman, AZJ 2005, 'Neurological syndromes which can be mistaken for psychiatric conditions', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 76, no. suppl 1, pp. i31–i38.

Cattaneo, E 2003, 'Dysfunction of wild-type huntingtin in Huntington disease', *News in Physiological Sciences: An International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society*, vol. 18, pp. 34–37.

Chen, B, Gilbert, LA, Cimini, BA, Schnitzbauer, J, Zhang, W, Li, G-W, Park, J, Blackburn, EH, Weissman, JS, Qi, LS & Huang, B 2013, 'Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system', *Cell*, vol. 155, no. 7, pp. 1479–1491.

Cong, L, Zhou, R, Kuo, Y-C, Cunniff, M & Zhang, F 2012, 'Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains', *Nature Communications*, vol. 3, p. 968.

Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N, Hsu, PD, Wu, X, Jiang, W, Marraffini, LA & Zhang, F 2013, 'Multiplex genome engineering using CRISPR/Cas systems', *Science (New York, N.Y.)*, vol. 339, no. 6121, pp. 819–823.

Cowan, CM & Raymond, LA 2006, 'Selective neuronal degeneration in Huntington's disease', *Current Topics in Developmental Biology*, vol. 75, pp. 25–71.

Cox, DBT, Platt, RJ & Zhang, F 2015, 'Therapeutic Genome Editing: Prospects and Challenges', *Nature medicine*, vol. 21, no. 2, pp. 121–131.

Cronshaw, JM, Krutchinsky, AN, Zhang, W, Chait, BT & Matunis, MJ 2002, 'Proteomic analysis of the mammalian nuclear pore complex', *The Journal of Cell Biology*, vol. 158, no. 5, pp. 915–927.

Cronshaw, JM & Matunis, MJ 2003, 'The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome', *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 10, pp. 5823–5827.

Dang, Y, Jia, G, Choi, J, Ma, H, Anaya, E, Ye, C, Shankar, P & Wu, H 2015, 'Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency', *Genome Biology*, vol. 16, p. 280.

Dartt, DA 2009, 'Neural Regulation of Lacrimal Gland Secretory Processes: Relevance in Dry Eye Diseases', *Progress in retinal and eye research*, vol. 28, no. 3, pp. 155–177.

Dayalu, P & Albin, RL 2015, 'Huntington Disease: Pathogenesis and Treatment', *Neurologic Clinics*, vol. 33, Movement Disorders, no. 1, pp. 101–114.

De Rooij, KE, Dorsman, JC, Smoor, MA, Den Dunnen, JT & Van Ommen, GJ 1996, 'Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation', *Human Molecular Genetics*, vol. 5, no. 8, pp. 1093–1099.

Dimos, JT, Rodolfa, KT, Niakan, KK, Weisenthal, LM, Mitsumoto, H, Chung, W, Croft, GF, Saphier, G, Leibel, R, Goland, R, Wichterle, H, Henderson, CE & Eggan, K 2008, 'Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons', *Science (New York, N.Y.)*, vol. 321, no. 5893, pp. 1218–1221.

Doudna, JA & Charpentier, E 2014, 'Genome editing. The new frontier of genome engineering with CRISPR-Cas9', *Science (New York, N.Y.)*, vol. 346, no. 6213, p. 1258096.

Duan, W, Jiang, M & Jin, J 2014, 'Metabolism in HD - Still a relevant mechanism?', *Movement disorders : official journal of the Movement Disorder Society*, vol. 29, no. 11, pp. 1366–1374.

Dumic, M, Barišic, N, Kusec, V, Stingl, K, Skegro, M, Stanimirovic, A, Koehler, K & Huebner, A 2012, 'Long-term clinical follow-up and molecular genetic findings in eight patients with triple A syndrome', *European Journal of Pediatrics*, vol. 171, no. 10, pp. 1453–1459.

Duyao, M, Ambrose, C, Myers, R, Novelletto, A, Persichetti, F, Frontali, M, Folstein, S, Ross, C, Franz, M & Abbott, M 1993, 'Trinucleotide repeat length instability and age of onset in Huntington's disease', *Nature Genetics*, vol. 4, no. 4, pp. 387–392.

Ebert, AD, Liang, P & Wu, JC 2012, 'Induced pluripotent stem cells as a disease modeling and drug screening platform', *Journal of Cardiovascular Pharmacology*, vol. 60, no. 4, pp. 408–416.

European Commission 2016, *Neurodegenerative Disorders - European Commission*, viewed 15 May 2016, http://ec.europa.eu/health/major_chronic_diseases/diseases/brain_neurological/index_en.htm>.

Frank, S 2014, 'Treatment of Huntington's disease', *Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics*, vol. 11, no. 1, pp. 153–160.

Fu, Y, Sander, JD, Reyon, D, Cascio, VM & Joung, JK 2014, 'Improving CRISPR-Cas nuclease specificity using truncated guide RNAs', *Nature Biotechnology*, vol. 32, no. 3, pp. 279–284.

Gianaros, PJ, Jennings, JR, Sheu, LK, Greer, PJ, Kuller, LH & Matthews, KA 2007, 'Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus', *NeuroImage*, vol. 35, no. 2, pp. 795–803.

Grant, DB, Barnes, ND, Dumic, M, Ginalska-Malinowska, M, Milla, PJ, von Petrykowski, W, Rowlatt, RJ, Steendijk, R, Wales, JH & Werder, E 1993, 'Neurological and adrenal dysfunction in the adrenal insufficiency/alacrima/achalasia (3A) syndrome', *Archives of Disease in Childhood*, vol. 68, no. 6, pp. 779–782.

Guo, J, Gaj, T & Barbas, CF 2010, 'Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases', *Journal of Molecular Biology*, vol. 400, no. 1, pp. 96–107.

Gupta, RM & Musunuru, K 2014, 'Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9', *The Journal of Clinical Investigation*, vol. 124, no. 10, pp. 4154–4161.

Handschug, K, Sperling, S, Yoon, SJ, Hennig, S, Clark, AJ & Huebner, A 2001, 'Triple A syndrome is caused by mutations in *AAAS*, a new WD-repeat protein gene', *Human Molecular Genetics*, vol. 10, no. 3, pp. 283–290.

Harper, B 2005, 'Huntington disease', *Journal of the Royal Society of Medicine*, vol. 98, no. 12, p. 550.

Hau, J & Schapiro, SJ 2010, Handbook of Laboratory Animal Science, Volume I, Third Edition: Essential Principles and Practices, CRC Press.

Hirano, M, Furiya, Y, Asai, H, Yasui, A & Ueno, S 2006, 'ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome', *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 7, pp. 2298–2303.

Hodgkins, A, Farne, A, Perera, S, Grego, T, Parry-Smith, DJ, Skarnes, WC & Iyer, V 2015, 'WGE: a CRISPR database for genome engineering', *Bioinformatics (Oxford, England)*, vol. 31, no. 18, pp. 3078–3080.

Hodgson, JG, Agopyan, N, Gutekunst, C-A, Leavitt, BR, LePiane, F, Singaraja, R, Smith, DJ, Bissada, N, McCutcheon, K, Nasir, J, Jamot, L, Li, X-J, Stevens, ME, Rosemond, E, Roder, JC, Phillips, AG, Rubin, EM, Hersch, SM & Hayden, MR 1999, 'A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration', *Neuron*, vol. 23, no. 1, pp. 181–192.

Houlden, H, Smith, S, Carvalho, M de, Blake, J, Mathias, C, Wood, NW & Reilly, MM 2002, 'Clinical and genetic characterization of families with triple A (Allgrove) syndrome', *Brain*, vol. 125, no. 12, pp. 2681–2690.

Hsu, PD, Lander, ES & Zhang, F 2014, 'Development and Applications of CRISPR-Cas9 for Genome Engineering', *Cell*, vol. 157, no. 6, pp. 1262–1278.

Hu, JH, Davis, KM & Liu, DR 2016, 'Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases', *Cell Chemical Biology*, vol. 23, no. 1, pp. 57–73.

Huang, B-W, Ray, PD, Iwasaki, K & Tsuji, Y 2013, 'Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4', *The FASEB Journal*, vol. 27, no. 9, pp. 3763–3774.

Huangfu, D, Osafune, K, Maehr, R, Guo, W, Eijkelenboom, A, Chen, S, Muhlestein, W & Melton, DA 2008, 'Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2', *Nature Biotechnology*, vol. 26, no. 11, pp. 1269–1275.

Huebner, A, Elias, LL & Clark, AJ 1999, 'ACTH resistance syndromes', *Journal of pediatric endocrinology & metabolism: JPEM*, vol. 12 Suppl 1, pp. 277–293.

Huebner, A, Kaindl, AM, Knobeloch, KP, Petzold, H, Mann, P & Koehler, K 2004, 'The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex', *Endocrine Research*, vol. 30, no. 4, pp. 891–899.

Huebner, A, Mann, P, Rohde, E, Kaindl, AM, Witt, M, Verkade, P, Jakubiczka, S, Menschikowski, M, Stoltenburg-Didinger, G & Koehler, K 2006, 'Mice lacking the nuclear pore complex protein ALADIN show female infertility but fail to develop a phenotype resembling human triple A syndrome', *Molecular and Cellular Biology*, vol. 26, no. 5, pp. 1879–1887.

Hunter, P 2008, 'The paradox of model organisms. The use of model organisms in research will continue despite their shortcomings', *EMBO Reports*, vol. 9, no. 8, pp. 717–720.

Iyer, V, Shen, B, Zhang, W, Hodgkins, A, Keane, T, Huang, X & Skarnes, WC 2015, 'Off-target mutations are rare in Cas9-modified mice', *Nature Methods*, vol. 12, no. 6, p. 479.

Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, JA & Charpentier, E 2012, 'A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity', *Science* (*New York, N.Y.*), vol. 337, no. 6096, pp. 816–821.

Kallabi, F, Ben Rhouma, B, Baklouti, S, Ghorbel, R, Felhi, R, Keskes, L & Kamoun, H 2016, 'Splicing Defects in the *AAAS* Gene Leading to both Exon Skipping and Partial Intron Retention in a Tunisian Patient with Allgrove Syndrome', *Hormone Research in Paediatrics*, vol. 86, no. 2, pp. 90–93.

Kast, P 1994, 'pKSS--a second-generation general purpose cloning vector for efficient positive selection of recombinant clones', *Gene*, vol. 138, no. 1–2, pp. 109–114.

Kim, HS, Bernitz, JM, Lee, D-F & Lemischka, IR 2014, 'Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells', *Stem Cells and Development*, vol. 23, no. 22, pp. 2673–2686.

Kind, B, Koehler, K, Lorenz, M & Huebner, A 2009, 'The nuclear pore complex protein ALADIN is anchored via NDC1 but not via POM121 and GP210 in the nuclear envelope', *Biochemical and Biophysical Research Communications*, vol. 390, no. 2, pp. 205–210.

Kind, B, Koehler, K, Krumbholz, M, Landgraf, D & Huebner, A 2010, 'Intracellular ROS level is increased in fibroblasts of triple A syndrome patients', *Journal of Molecular Medicine* (*Berlin, Germany*), vol. 88, no. 12, pp. 1233–1242.

Kiriyama, T, Hirano, M, Asai, H, Ikeda, M, Furiya, Y & Ueno, S 2008, 'Restoration of nuclearimport failure caused by triple A syndrome and oxidative stress', *Biochemical and Biophysical Research Communications*, vol. 374, no. 4, pp. 631–634.

Krumbholz, M, Koehler, K & Huebner, A 2006, 'Cellular localization of 17 natural mutant variants of ALADIN protein in triple A syndrome - shedding light on an unexpected splice mutation', *Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire*, vol. 84, no. 2, pp. 243–249.

Landles, C & Bates, GP 2004, 'Huntingtin and the molecular pathogenesis of Huntington's disease', *EMBO Reports*, vol. 5, no. 10, pp. 958–963.

Langbehn, DR, Brinkman, RR, Falush, D, Paulsen, JS, Hayden, MR & International Huntington's Disease Collaborative Group 2004, 'A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length', *Clinical Genetics*, vol. 65, no. 4, pp. 267–277.

Li, SH, Gutekunst, CA, Hersch, SM & Li, XJ 1998, 'Interaction of huntingtin-associated protein with dynactin P150Glued', *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, vol. 18, no. 4, pp. 1261–1269.

Li, D & Roberts, R 2001, 'WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases', *Cellular and molecular life sciences: CMLS*, vol. 58, no. 14, pp. 2085–2097.

Li, S-H & Li, X-J 2004, 'Huntingtin and its role in neuronal degeneration', *The Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry*, vol. 10, no. 5, pp. 467–475.

Lin, MT & Beal, MF 2006, 'Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases', *Nature*, vol. 443, no. 7113, pp. 787–795.

Mali, P, Yang, L, Esvelt, KM, Aach, J, Guell, M, DiCarlo, JE, Norville, JE & Church, GM 2013, 'RNA-guided human genome engineering via Cas9', *Science (New York, N.Y.)*, vol. 339, no. 6121, pp. 823–826.

Marshall, J, White, K, Weaver, M, Flury Wetherill, L, Hui, S, Stout, JC, Johnson, SA, Beristain, X, Gray, J, Wojcieszek, J & Foroud, T 2007, 'Specific psychiatric manifestations among preclinical Huntington disease mutation carriers', *Archives of Neurology*, vol. 64, no. 1, pp. 116–121.

Mattson, MP 2000, 'Apoptosis in neurodegenerative disorders', *Nature Reviews Molecular Cell Biology*, vol. 1, no. 2, pp. 120–130.

Mazzone, L, Postorino, V, De Peppo, L, Vassena, L, Fatta, L, Armando, M, Giuseppe, Cappa, M, Vicari, S, Mazzone, L, Postorino, V, De Peppo, L, Vassena, L, Fatta, L, Armando, M, Scirè, Giuseppe, Cappa, M & Vicari, S 2013, 'Longitudinal Neuropsychological Profile in a Patient with Triple A Syndrome', *Case Reports in Pediatrics, Case Reports in Pediatrics*, vol. 2013, 2013, p. e604921.

Medvedev, SP, Shevchenko, AI & Zakian, SM 2010, 'Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine', *Acta Naturae*, vol. 2, no. 2, pp. 18–28.

Merkle, FT & Eggan, K 2013, 'Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function', *Cell Stem Cell*, vol. 12, no. 6, pp. 656–668.

Miller, JC, Tan, S, Qiao, G, Barlow, KA, Wang, J, Xia, DF, Meng, X, Paschon, DE, Leung, E, Hinkley, SJ, Dulay, GP, Hua, KL, Ankoudinova, I, Cost, GJ, Urnov, FD, Zhang, HS, Holmes, MC, Zhang, L, Gregory, PD & Rebar, EJ 2011, 'A TALE nuclease architecture for efficient genome editing', *Nature Biotechnology*, vol. 29, no. 2, pp. 143–148.

Mitchell, IJ, Cooper, AJ & Griffiths, MR 1999, 'The selective vulnerability of striatopallidal neurons', *Progress in Neurobiology*, vol. 59, no. 6, pp. 691–719.

Morton, AJ 2013, 'Circadian and sleep disorder in Huntington's disease', *Experimental Neurology*, vol. 243, Circadian rhythms and sleep disorders, pp. 34–44.

Mullaney, PB, Weatherhead, R, Millar, L, Ayyash, LI, Ayberk, H, Cai, F & Risco, JM 1998, 'Keratoconjunctivitis sicca associated with achalasia of the cardia, adrenocortical insufficiency, and lacrimal gland degeneration: Keratoconjunctivitis sicca secondary to lacrimal gland degeneration may parallel degenerative changes in esophageal and adrenocortical function', *Ophthalmology*, vol. 105, no. 4, pp. 643–650.

Nance, MA & Myers, RH 2001, 'Juvenile onset Huntington's disease--clinical and research perspectives', *Mental Retardation and Developmental Disabilities Research Reviews*, vol. 7, no. 3, pp. 153–157.

Neer, EJ, Schmidt, CJ, Nambudripad, R & Smith, TF 1994, 'The ancient regulatory-protein family of WD-repeat proteins', *Nature*, vol. 371, no. 6495, pp. 297–300.

Nieoullon, A 2011, 'Neurodegenerative diseases and neuroprotection: current views and prospects', *Journal of Applied Biomedicine*, vol. 9, no. 4, pp. 173–183.

Nowak, CM, Lawson, S, Zerez, M & Bleris, L 2016, 'Guide RNA engineering for versatile Cas9 functionality', *Nucleic Acids Research*, p. gkw908.

Pavletich, NP & Pabo, CO 1991, 'Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A', *Science*, vol. 252, no. 5007, pp. 809–817.

Prasad, R, Metherell, LA, Clark, AJ & Storr, HL 2013, 'Deficiency of ALADIN Impairs Redox Homeostasis in Human Adrenal Cells and Inhibits Steroidogenesis', *Endocrinology*, vol. 154, no. 9, pp. 3209–3218.

Prasad, R, Kowalczyk, JC, Meimaridou, E, Storr, HL & Metherell, LA 2014, 'Oxidative stress and adrenocortical insufficiency', *Journal of Endocrinology*, vol. 221, no. 3, pp. R63–R73.

Prpic, I, Huebner, A, Persic, M, Handschug, K & Pavletic, M 2003, 'Triple A syndrome: Genotype-phenotype assessment', *Clinical Genetics*, vol. 63, no. 5, pp. 415–417.

Ran, FA, Hsu, PD, Lin, C-Y, Gootenberg, JS, Konermann, S, Trevino, AE, Scott, DA, Inoue, A, Matoba, S, Zhang, Y & Zhang, F 2013, 'Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity', *Cell*, vol. 154, no. 6, pp. 1380–1389.

Rangone, H, Humbert, S & Saudou, F 2004, 'Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?', *Pathologie-Biologie*, vol. 52, no. 6, pp. 338–342.

Richards, WG & Sugarbaker, DJ 1995, 'Neuronal control of esophageal function', *Chest Surgery Clinics of North America*, vol. 5, no. 1, pp. 157–171.

Rosenblatt, A 2007, 'Neuropsychiatry of Huntington's disease', *Dialogues in Clinical Neuroscience*, vol. 9, no. 2, pp. 191–197.

Sarathi, V & Shah, NS 2010, 'Triple-a syndrome', *Advances in Experimental Medicine and Biology*, vol. 685, pp. 1-8.

Saudou, F, Finkbeiner, S, Devys, D & Greenberg, ME 1998, 'Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions', *Cell*, vol. 95, no. 1, pp. 55–66.

Semaka, A, Creighton, S, Warby, S & Hayden, MR 2006, 'Predictive testing for Huntington disease: interpretation and significance of intermediate alleles', *Clinical Genetics*, vol. 70, no. 4, pp. 283–294.

Shen, Z, Sathyan, KM, Geng, Y, Zheng, R, Chakraborty, A, Freeman, B, Wang, F, Prasanth, KV & Prasanth, SG 2010, 'A WD-Repeat Protein Stabilizes ORC Binding to Chromatin', *Molecular Cell*, vol. 40, no. 1, pp. 99–111.

Shen, B, Zhang, W, Zhang, J, Zhou, J, Wang, J, Chen, L, Wang, L, Hodgkins, A, Iyer, V, Huang, X & Skarnes, WC 2014, 'Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects', *Nature Methods*, vol. 11, no. 4, pp. 399–402.

Skarnes, WC, Rosen, B, West, AP, Koutsourakis, M, Bushell, W, Iyer, V, Mujica, AO, Thomas, M, Harrow, J, Cox, T, Jackson, D, Severin, J, Biggs, P, Fu, J, Nefedov, M, de Jong,

PJ, Stewart, AF & Bradley, A 2011, 'A conditional knockout resource for the genome-wide study of mouse gene function', *Nature*, vol. 474, no. 7351, pp. 337–342.

Slow, EJ, Graham, RK & Hayden, MR 2006, 'To be or not to be toxic: aggregations in Huntington and Alzheimer disease', *Trends in genetics: TIG*, vol. 22, no. 8, pp. 408–411.

Small, SA 2003, 'Measuring correlates of brain metabolism with high-resolution MRI: a promising approach for diagnosing Alzheimer disease and mapping its course', *Alzheimer Disease and Associated Disorders*, vol. 17, no. 3, pp. 154–161.

Smih, F, Rouet, P, Romanienko, PJ & Jasin, M 1995, 'Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells.', *Nucleic Acids Research*, vol. 23, no. 24, pp. 5012–5019.

Smith, TF 2008, 'Diversity of WD-repeat proteins', *Sub-cellular Biochemistry*, vol. 48, pp. 20–30.

Spires, TL, Grote, HE, Varshney, NK, Cordery, PM, van Dellen, A, Blakemore, C & Hannan, AJ 2004, 'Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism', *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, vol. 24, no. 9, pp. 2270–2276.

Storr, HL, Clark, AJL, Priestley, JV & Michael, GJ 2005, 'Identification of the sites of expression of triple a syndrome mRNA in the rat using in situ hybridisation', *Neuroscience*, vol. 131, no. 1, pp. 113–123.

Storr, HL, Kind, B, Parfitt, DA, Chapple, JP, Lorenz, M, Koehler, K, Huebner, A & Clark, AJL 2009, 'Deficiency of Ferritin Heavy-Chain Nuclear Import in Triple A Syndrome Implies Nuclear Oxidative Damage as the Primary Disease Mechanism', *Molecular Endocrinology*, vol. 23, no. 12, pp. 2086–2094.

Streubel, J, Blücher, C, Landgraf, A & Boch, J 2012, 'TAL effector RVD specificities and efficiencies', *Nature Biotechnology*, vol. 30, no. 7, pp. 593–595.

Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K & Yamanaka, S 2007, 'Induction of pluripotent stem cells from adult human fibroblasts by defined factors', *Cell*, vol. 131, no. 5, pp. 861–872.

Takahashi, K & Yamanaka, S 2006, 'Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors', *Cell*, vol. 126, no. 4, pp. 663–676.

Terns, RM & Terns, MP 2014, 'CRISPR-based technologies: prokaryotic defense weapons repurposed', *Trends in genetics: TIG*, vol. 30, no. 3, pp. 111–118.

The Huntington's Disease Collaborative Research Group 1993, 'A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group', *Cell*, vol. 72, no. 6, pp. 971–983.

Thompson, KJ, Fried, MG, Ye, Z, Boyer, P & Connor, JR 2002, 'Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei', *Journal of Cell Science*, vol. 115, no. Pt 10, pp. 2165–2177.

Thompson, LM 2008, 'Neurodegeneration: A question of balance', *Nature*, vol. 452, no. 7188, pp. 707–708.

Thomson, JA, Itskovitz-Eldor, J, Shapiro, SS, Waknitz, MA, Swiergiel, JJ, Marshall, VS & Jones, JM 1998, 'Embryonic Stem Cell Lines Derived from Human Blastocysts', *Science*, vol. 282, no. 5391, pp. 1145–1147.

Tullio-Pelet, A, Salomon, R, Hadj-Rabia, S, Mugnier, C, De, L, Chaouachi, B, Bakiri, F, Brottier, P, Cattolico, L, Penet, C, Bégeot, M, Naville, D, Nicolino, M, Chaussain, J-L, Weissenbach, J, Munnich, A & Lyonnet, S 2000, 'Mutant WD-repeat protein in triple-A syndrome', *Nature Genetics*, vol. 26, no. 3, pp. 332–335.

Turner, C & Schapira, AHV 2010, 'Mitochondrial matters of the brain: the role in Huntington's disease', *Journal of Bioenergetics and Biomembranes*, vol. 42, no. 3, pp. 193–198.

UniProt Knowledgebase 2016, AAAS - Aladin - Homo sapiens (Human) - AAAS gene & protein, UniProt Knowledgebase, viewed 11 November 2016, <<u>http://www.uniprot.org/uniprot/Q9NRG9</u>>

Urnov, FD, Rebar, EJ, Holmes, MC, Zhang, HS & Gregory, PD 2010, 'Genome editing with engineered zinc finger nucleases', *Nature Reviews Genetics*, vol. 11, no. 9, pp. 636–646.

Van Dellen, A, Grote, HE & Hannan, AJ 2005, 'Gene–Environment Interactions, Neuronal Dysfunction and Pathological Plasticity in Huntington's Disease', *Clinical and Experimental Pharmacology and Physiology*, vol. 32, no. 12, pp. 1007–1019.

Vishnu, VY, Modi, M, Prabhakar, S, Bhansali, A & Goyal, MK 2014, "A" motor neuron disease', *Journal of the Neurological Sciences*, vol. 336, no. 1–2, pp. 251–253.

Walker, FO 2007, 'Huntington's disease', *Lancet (London, England)*, vol. 369, no. 9557, pp. 218–228.

Wang, H, Bian, X, Xia, L, Ding, X, Müller, R, Zhang, Y, Fu, J & Stewart, AF 2014, 'Improved seamless mutagenesis by recombineering using ccdB for counterselection', *Nucleic Acids Research*, vol. 42, no. 5, p. e37.

Wang, L, Li, F, Dang, L, Liang, C, Wang, C, He, B, Liu, J, Li, D, Wu, X, Xu, X, Lu, A & Zhang, G 2016, '*In Vivo* Delivery Systems for Therapeutic Genome Editing', *International Journal of Molecular Sciences*, vol. 17, no. 5, viewed 25 November 2016, ">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881452/>.

Wert, G de & Mummery, C 2003, 'Human embryonic stem cells: research, ethics and policy', *Human Reproduction*, vol. 18, no. 4, pp. 672–682.

Winner, B, Kohl, Z & Gage, FH 2011, 'Neurodegenerative disease and adult neurogenesis', *European Journal of Neuroscience*, vol. 33, no. 6, pp. 1139–1151.

WHO 2016, *Neurological disorders affect millions globally: WHO report* WHO, viewed 24 November 2016, http://www.who.int/mediacentre/news/releases/2007/pr04/en/.

Wu, X, Kriz, AJ & Sharp, PA 2014, 'Target specificity of the CRISPR-Cas9 system', *Quantitative biology*, vol. 2, no. 2, pp. 59–70.

Yang, X 2015, 'Applications of CRISPR-Cas9 mediated genome engineering', *Military Medical Research*, vol. 2, viewed 25 November 2016, ">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433013/>.

Yoon, G, Kramer, J, Zanko, A, Guzijan, M, Lin, S, Foster-Barber, A & Boxer, AL 2006, 'Speech and language delay are early manifestations of juvenile-onset Huntington disease', *Neurology*, vol. 67, no. 7, pp. 1265–1267.

Young, AB 2003, 'Huntingtin in health and disease', *Journal of Clinical Investigation*, vol. 111, no. 3, pp. 299–302.

Young, MA, Larson, DE, Sun, C-W, George, DR, Ding, L, Miller, CA, Lin, L, Pawlik, KM, Chen, K, Fan, X, Schmidt, H, Kalicki-Veizer, J, Cook, LL, Swift, GW, Demeter, RT, Wendl, MC, Sands, MS, Mardis, ER, Wilson, RK, Townes, TM & Ley, TJ 2012, 'Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells', *Cell Stem Cell*, vol. 10, no. 5, pp. 570–582.

Zacharias, DG, Nelson, TJ, Mueller, PS & Hook, CC 2011, 'The Science and Ethics of Induced Pluripotency: What Will Become of Embryonic Stem Cells?', *Mayo Clinic Proceedings*, vol. 86, no. 7, pp. 634–640.

Zeitlin, S, Liu, JP, Chapman, DL, Papaioannou, VE & Efstratiadis, A 1995, 'Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue', *Nature Genetics*, vol. 11, no. 2, pp. 155–163.

Zuris, JA, Thompson, DB, Shu, Y, Guilinger, JP, Bessen, JL, Hu, JH, Maeder, ML, Joung, JK, Chen, Z-Y & Liu, DR 2015, 'Efficient Delivery of Genome-Editing Proteins *In Vitro* and *In Vivo*', *Nature biotechnology*, vol. 33, no. 1, pp. 73–80.